Crossfund Sicav - Crossinvest Healthcare Fund A USD

Reference Data

ISIN LU1334634299
Valor Number 30671916
Bloomberg Global ID
Fund Name Crossfund Sicav - Crossinvest Healthcare Fund A USD
Fund Provider Crossinvest SA Lugano, Switzerland
Phone: +41 91 911 88 88
E-Mail: info@crossinvest.ch
Web: www.crossinvest.ch
Fund Provider Crossinvest SA
Representative in Switzerland FundPartner Solutions (Suisse) SA
Genève 75
Distributor(s) FundPartner Solutions (Suisse) SA
Genève 3
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition Combination of issuing commission charged by the fund management company and transaction fee charged by the fund
Redemption Condition Combination of redemption commission charged by the fund management company and transaction fee charged by the fund
Investment Strategy *** The investment objective of the Sub‐Fund is to achieve a long term capital appreciation by pursuing sector focus exposure opportunities in companies involved in health and personal care. These companies could participate in the research, clinical development or commercialization of medicines, equipment or services for disease treatment or life style improvement. The investment focus will be on industry leaders that offer premium growth and/or profitability prospects, pipeline and valuation upside. The Sub‐Fund is actively managed. The Sub‐Fund has no benchmark index and is not managed in reference to a benchmark index.
Peculiarities

Fund Prices

Current Price * 165.34 USD 30.10.2024
Previous Price * 166.69 USD 29.10.2024
52 Week High * 178.62 USD 30.08.2024
52 Week Low * 141.10 USD 10.11.2023
NAV * 165.34 USD 30.10.2024
Issue Price * 165.34 USD 30.10.2024
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 76,656,825
Unit/Share Assets *** 11,371,809
Trading Information SIX

Performance

YTD Performance +6.51% 29.12.2023
30.10.2024
YTD Performance (in CHF) +9.64% 29.12.2023
30.10.2024
1 month -4.02% 30.09.2024
30.10.2024
3 months -3.05% 30.07.2024
30.10.2024
6 months +2.99% 30.04.2024
30.10.2024
1 year +18.85% 30.10.2023
30.10.2024
2 years +8.96% 31.10.2022
30.10.2024
3 years -2.38% 02.11.2021
30.10.2024
5 years +30.94% 30.10.2019
30.10.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 9.38%
Novo Nordisk AS Class B 5.96%
Merck & Co Inc 4.37%
AbbVie Inc 4.36%
Johnson & Johnson 4.30%
UnitedHealth Group Inc 4.20%
AstraZeneca PLC 3.98%
Novartis AG Registered Shares 3.40%
Stryker Corp 3.20%
Edwards Lifesciences Corp 2.94%
Last data update 30.06.2024

Cost / Risk

TER
TER date
Performance Fee *** 15.00%
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.98%
SRRI ***
SRRI date *** 30.09.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 ***

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)